Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals ...
Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, ...
Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the ...
Alnylam shares dropped by a quarter on Thursday, with analysts suggesting the decline puts the RNAi specialist within range ...
Raises Full Year 2026 Revenue and Cash Outlook on Continued Business Momentum Conference Call to Begin Today at 8:00 a.m. ET.
Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit ...
TOKYO-- (BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ...
Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s ...
FEV1, FVC and other spirometric measures with 28 days of dosing in moderate to severe COPD patients. Fexlamose did not ...
Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, ...
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically ...
CLIA certification is a U.S. regulatory requirement for laboratories performing testing on specimens from humans, such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results